AnaptysBio Inc to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event Transcript
Good day, and thank you for standing by. Welcome to the Anaptys PD-1 Agonist Rosnilimab R&D Event Webcast. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to Dan Faga, President and Chief Executive Officer of Anaptys.
Welcome, everyone. We are excited to host today's event focused on rosnilimab, our internally discovered PD-1 agonist. This presentation will contain statements that are forward looking. We're going to review what are massive opportunities for rosnilimab with a best-in-class profile in rheumatoid arthritis, where there is proof-of-concept for this mechanism and announcing today a first-in-class study in ulcerative colitis.
Joining me from Anaptys are Dr. Paul Lizzul, our Chief Medical Officer; Dr. Martin Dahl, our SVP of Research; and Dr. Cailin Sibley, our VP, Translational Medicine. Also, we've had 2 distinguished physicians prerecord their sessions. Dr. Jonathan Graf, Professor
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |